SEARCH

SEARCH BY CITATION

References

  • 1
    DGVS. (2001) Diagnostik und Therapie der Colitis ulcerosa – Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 2001; 39: 1972.
  • 2
    Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. Dig Dis Sci 1993; 38(10): 184350.
  • 3
    Campieri M, et al.Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32: 92931.
  • 4
    Campieri M, Lanfranchi GA, Bazzocchi G, et al.Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; August 8: 2701.
  • 5
    Hanauer SB, Kane SV, Guernsey B, et al.Randomized clinical trial of mesalamine (5-ASA)-enemas in distal ulcerative colitis: a dose-ranging placebo controlled study. Gastroenterology 1989; 96: A195A195(Abstract).
  • 6
    Pullan RD, Ganesh S, Mani V, et al.Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993; 34: 6769.
  • 7
    Lee FI, Jewell DP, Mani V, et al.A randomised trial comparing mesalazine and prednisolone foam enemas in patients with active distal ulcerative colitis. Gut 1996; 38: 22933.
  • 8
    Ardizzone S, Doldo P, Ranzi T, et al.Mesalazine foam (Salofalk® foam) in the treatment of active distal ulcerative colitis. Ital J Gastroenterol Hepatol 1999; 31: 67784.
  • 9
    Campieri M, Corbelli C, Gionchetti P, et al.Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992; 37: 18907.
  • 10
    Wilding IR, Kenyon CJ, Chavhan S, et al.Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 1616.
  • 11
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 826.
  • 12
    Irvine EJ, Feagan B, Ronchon J, et al.Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 28796.
  • 13
    De Boer AGEM, Wijker W, Bartelsman JFW, De Haes CJM. Inflammatory bowel disease questionnaire. cross-cultural adaptation and further validation. Eur J Gastroenterol Hepatol 1995; 7: 104350.
  • 14
    Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 11918.DOI: 10.1046/j.1365-2036.2000.00784.x
  • 15
    Hanauer SB. Dose-ranging study of mesalazine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflammatory Bowel Dis 1998; 4(2): 7883.
  • 16
    Sutherland LR. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987; 92(6): 18948.